Alumis Inc.

Alumis Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for immune-mediated diseases, aiming to replace broad immunosuppression with precision medicines. The company leverages its proprietary precision data analytics platform, biological insights, and expertise in immunology to advance a late-stage portfolio of next-generation treatments. Key pipeline assets include ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor targeting plaque psoriasis and systemic lupus erythematosus; A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases; and programs addressing interferon regulatory factor 5 (IRF5) to correct immune dysfunction. Alumis Inc. focuses on optimizing patient outcomes across autoimmune disorders through innovative drug discovery, development, and potential commercialization efforts. Founded in 2021 and headquartered in South San Francisco, California, the company plays a significant role in the biotechnology sector by pioneering therapies that transform treatment paradigms for chronic immune conditions.